NDAINHALATIONAEROSOL, METERED
Approved
Jan 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
AEROSPAN HFA (flunisolide) by Roche is clinical pharmacology flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. First approved in 2006.
Drug data last refreshed 4h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AEROSPAN HFA (flunisolide) is an inhaled corticosteroid delivered via metered-dose aerosol for treatment of allergic and non-allergic rhinitis. It works as a potent glucocorticoid that exerts local anti-inflammatory effects on nasal mucous membranes with minimal systemic absorption at recommended doses. The drug provides rapid symptom relief for nasal congestion, rhinorrhea, and sneezing within days of initiation.
LOE Approaching
Product approaching loss of exclusivity with likely declining market share; team focus may shift toward lifecycle extension or support for generic transition.
Mechanism of Action
CLINICAL PHARMACOLOGY Flunisolide has demonstrated potent glucocorticoid and weak mineralocorticoid activity in classical animal test systems. As a glucocorticoid, it is several hundred times more potent than the cortisol standard. Clinical studies with flunisolide have shown therapeutic activity…
Worked on AEROSPAN HFA at Roche? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.